Presentations from the 34th annual conference in Dublin

Here you will find the poster and oral presentations which were made available by the presenters at the 34th annual conference in Dublin.

For presentations from previous meetings, please see here.

Here are the abstracts which were accepted for the meeting (for personal use only, please do not download or share the PDF)

Oral Presentations

Thursday Sessions (31st August 2023)

09.30 Medication exposure in pregnancy; What to look for using first and second trimester ultrasound and fetal echocardiography

Friday Sessions (1st September 2023)

09.00 Potential novel vaccines in pregnancy – Prof Richard Drew
09.25 Facilitators and barriers to maternal immunization, a global perspective – Dr Sarah Geoghegan
09.50 Long-term follow-up of children exposed to Zika during pregnancy – Prof Lavinia Schuler Faccini
10.15 Preparing for the next pandemic? Don’t leave pregnant women behind – Prof Susan Hopkins
11.20 Communicating the risk and benefits of medication use in pregnancy and breastfeeding – Dr María del Carmen Climént
11.55 Information provision and communication with minority groups and vulnerable populations – Prof Maeve Eogan
12.20 Pharmacoepidemiology in pregnancy: Challenges with interpretation and communication of findings – Prof Alice Panchaud
12.45 Panel discussion on risk communication and information provision: Challenges and Opportunities
13.10 Update from the ConcePTION project – IMI ConcePTION Team
14.30 Expert consensus on neurodevelopmental outcomes in pregnancy pharmacovigilance studies – Dr Rebecca Bromley
14.45 IMI ConcePTION core data elements for pregnancy pharmacovigilance studies using primary source data collection methods – Dr Jonathan Luke Richardson
15.00 A comparison of self-reported offspring’s congenital birth abnormalities with data provided by general practitioners; data from the Dutch Pregnancy Drug Register – Dr Veronique Maas
15.15 Use of medication for gastroesophageal reflux during pregnancy and adverse birth outcomes – Dr Marleen van Gelder
15.30 Post-conceptional exposure to clomiphene citrate and congenital malformations: a cohort study – Ms Rebeccah Nehard
15.45 Risk of major congenital malformation following maternal use of oral fluconazole during the first trimester of pregnancy: a systematic review and meta-analysis – Dr Mathilde Latour
16.00 Under publication, already out of date: need for living meta-analyses. Illustration from the metaPreg project, an innovative mode of dissemination living – Dr Cyndie Picot

Saturday Sessions (2nd September 2023)

09.00 The patient perspective – Ms Karen Keely
09.15 Epilepsy Genomics and Personalised Medicine in women with epilepsy: Implications for preconception, pregnancy and postpartum care – Prof Norman Delanty
09.55 An update on ASM and neurodevelopmental disorders – Dr Rebecca Bromley
10.20 Benefits and risks with folic supplementation in persons using antiseizure medication in pregnancy; Neurologist perspective – Prof Marte-Helene Bjørk
10.40 Benefits and risks with folic supplementation in persons using antiseizure medication in pregnancy; Maternal-Fetal Medicine perspective – Prof. Fionnuala McAuliffe
11.00 Discussion on folic acid supplementation in WWE
12.00 Neurodevelopmental outcomes in children and adults with Fetal Valproate Spectrum Disorder: a contribution from the ConcePTION project – Dr Matthew Bluett-Duncan
12.15 Lamotrigine exposure during lactation; Concentrations and effects in the newborn – Dr Ingrid Alvarez
12.30 Monitoring of lamotrigine concentrations in five breastfed newborns – Dr Marie-Andrée Thompson-Bos
12.45 Placental passage of lithium and neonatal complications after lithium exposure – Dr Katarina Töttermann
13.00 Artificial intelligence for determination of medication compatible with breastfeeding – Ms Maya Berlin

Poster Presentations

  1. A new Teratology Information Service in Milan: the experience from the first nine months – Maya Salimova and colleagues
  2. An observational study on safety of COVID-19 vaccines in pregnancy – current status and preliminary data based on the Embryotox cohort – Stephanie Padberg and colleagues
  3. Bisoprolol during breastfeeding: a prospective case series – Tal De- Haan and colleagues
  4. Breastfeeding during lithium therapy is safe in healthy full-term infants when monitored – Essi Heinonen and colleagues
  5. Breastfeeding Exposure to Agomelatine – preliminary findings from an Australian observational cohort study – Kwok S and colleagues
  6. Brivudine Exposure During Pregnancy and Infant Outcomes: Two Case Report – Nusret Uysal and colleagues
  7. Chronic medication and breastfeeding, avoiding behavior in Dutch women – Anneke Passier and colleagues
  8. Clinical Quality of Information of Primary Pregnancy Pharmacovigilance Data Sources – A ConcePTION Project – Yrea R.J. van Rijt-Weetink and colleagues
  9. Comparison of the safety of atypical antipsychotics used during pregnancy: a systematic review and network meta-analysis – Rachël Lefaivre and colleagues
  10. Consensus panel recommendations for management of pregnant women affects by anxiety and depressive disorders – Georgios Eleftheriou and colleagues
  11. Development of a toolkit to stimulate reporting and participation in studies/registries for pregnant and breastfeeding women – Alison Oliver and colleagues
  12. Don’t cry over spilt milk: Women treated with medications CAN (in many cases) donate milk to a Human Milk Bank – Tal De-Haan and colleagues
  13. Dopamine agonists pramipexole, ropinirole and rotigotine for the treatment of restless legs syndrome in pregnancy – Wolfgang E. Paulus and colleagues
  14. Evaluation of paternal drug use in a teratology information service – Onur Gültekin and colleagues
  15. Fertility treatment in Norway – What about breastfeeding during treatment? – Gro C. Havnen and colleagues
  16. Follow-up of breastfed infants exposed to maternal flecainide treatment – Véronique Pizzoglio and colleagues
  17. I am a law student treated with amphetamines for Attention Deficit Hyperactive Disorder (ADHD): Can I breastfeed my child? A pilot study – Ariela Hazan and colleagues
  18. Identifying safety concerns related to antiseizure medication use in breastfeeding women with epilepsy by reviewing questions to the Norwegian drug information and pharmacovigilance centres – Sunniva Reitan Riibe and colleagues
  19. Improving data collection in pregnancy safety studies: Towards standardization of data elements in pregnancy reports from public and private partners (ConcePTION) – Guillaume Favre and colleagues
  20. Iohexol exposure in the first trimester of the pregnancy, a case report – Mert Kaşkal and colleagues
  21. Isotretinoin cases in the Finnish TIS database – Maria Ellfolk and colleagues
  22. Medication use while breastfeeding – are there problems to solve? – Zagorodnikova K.* and colleagues
  23. Monotherapy treatment of epilepsy in pregnancy: Congenital malformation outcomes in the child – Sonia Khanom and colleagues
  24. NSAIDs exposure during late pregnancy: trends in prescriptions and reporting fetal adverse effects – Fatiha Karam and colleagues
  25. Olmesartan-induced reversible transaminase elevation in a breastfed newborn. A case report – Maya Salimova and colleagues
  26. Paternal smoking and maternal Secondhand Smoke (SHS) exposure: Results from the EHF (Environmental Health Fund) Birth Cohort – Maya Berlin and colleagues
  27. Pharmacists’ experiences of using knowledge bases on medicines in pregnancy and breastfeeding – Ulrika Nörby and colleagues
  28. Pregnancy and neonatal outcome following agomelatine and pipamperone exposure during pregnancy: a case series from the Netherlands – Michael Ceulemans and colleagues
  29. Pregnancy Outcome after Erenumab Treatment during early Pregnancy: a Case Series – Ariane Wahliß and colleagues
  30. Pregnancy Outcomes Following Maternal Favipiravir Exposure: A Case Series – Baris Karadas and colleagues
  31. Pregnancy outcomes of anti-TNF-alfa treatment during pregnancy: A mixed case series – Aylin Toplu and colleagues
  32. Prenatal Cannabis Exposure and the Risk for Neuropsychiatric Anomalies in the Offspring: A Systematic Review and Meta-Analysis – Noa Yakirevich Amir and colleagues
  33. Profile of calls and activities of the first Teratogen Information Service in Latin America through 32 years – Lavínia Schuler-Faccini and colleagues
  34. Quetiapine intake and milk ejection reflex in a breastfeeding woman: a case report – Anneke Passier and colleagues
  35. Safety of Covid-19 vaccination during pregnancy – the Finnish TIS experience – Melinda Gonzalez and colleagues
  36. Safety of monoclonal antibodies targeting PCSK9 in pregnancy: analysis of the WHO’s global pharmacovigilance database – Roberta Noseda and colleagues
  37. The BELpREG registration system on perinatal medication use and mother-infant outcomes: preliminary insights into the cohort’s characteristics – Laure Sillis and colleagues
  38. The development of a mobile app to inform pregnant women and their healthcare providers about the safety of over-the-counter medicines during pregnancy and breastfeeding – Veronique Y.F. Maas and colleagues
  39. The prevalence and type of safety questions on paternal medication use: a cross-sectional analysis in Belgium – Laure Sillis and colleagues
  40. The risk of miscarriage or preterm labor after COVID-19 vaccination before and during pregnancy – Maud de Feijter and colleagues
  41. The use of ondansetron in the first trimester: any differences after the EMA PRAC recommendation to not use it? – Annerose E. van der Mijle and colleagues
  42. Thiopurines use during pregnancy: a systematic review and updated meta-analysis of observational studies  – Sacha Rabeuf and colleagues
  43. Vitamin D macro dosing in pregnancy: a case report of D hypervitaminosis in pregnancy according to non-conventional Coimbra protocol and perinatal toxicity – Cecilia Lanzi and colleagues